High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

High-dose ipilimumab (IPI) and high-dose interleukin-2 (IL-2) are approved agents for metastatic melanoma, but the efficacy and safety of the combination are unknown. The objective of this study was to evaluate the feasibility, safety, and efficacy of combination high-dose IPI and high-dose IL-2 in...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Oncol
Auteurs principaux: Silk, Ann W., Kaufman, Howard L., Curti, Brendan, Mehnert, Janice M., Margolin, Kim, McDermott, David, Clark, Joseph, Newman, Jenna, Bommareddy, Praveen K., Denzin, Lisa, Najmi, Saltanat, Haider, Azra, Shih, Weichung, Kane, Michael P., Zloza, Andrew
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2020
Sujets:
Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6965158/
https://ncbi.nlm.nih.gov/pubmed/31998643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01483
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires